A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients with Migraine

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223375

Enrollment

Unknown

Registered

2016-11-13

Start date

2016-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

investigational material(s) Generic name etc : Galcanezumab INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients are 18 to 65 years of age - For Episodic Migraine participants: Participants who completed the treatment period of Galcanezumab Placebo-Controlled Study. - Have a diagnosis of chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.3) (ICHD-3 2013).

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026